Protalix BioTherapeutics, Inc. (PLX) Bundle
An Overview of Protalix BioTherapeutics, Inc. (PLX)
General Summary of Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing proprietary therapeutic proteins and recombinant enzymes. The company was founded in 1993 and is headquartered in Carmiel, Israel.
Key Products and Services
- ELELYSO (taliglucerase alfa) for Gaucher disease
- PRX-102 for Fabry disease
- OPRX-106 for inflammatory bowel disease
Company Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $84.2 million |
| Net Loss | ($37.6 million) |
| Cash and Cash Equivalents | $45.3 million |
Market Position
Protalix BioTherapeutics specializes in rare disease treatments using proprietary ProCellEx protein expression platform.
| Market Segment | Market Share |
|---|---|
| Rare Enzyme Replacement Therapies | 3.5% |
| Recombinant Protein Development | 2.8% |
Research and Development
- R&D Expenses in 2023: $22.1 million
- Active Clinical Trials: 3 ongoing programs
- Patent Portfolio: 45 granted patents
Mission Statement of Protalix BioTherapeutics, Inc. (PLX)
Mission Statement of Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. focuses on developing and commercializing novel therapeutics for rare and specialized diseases using its proprietary ProCellEx protein expression platform.
Core Mission Components
| Component | Specific Focus |
|---|---|
| Rare Disease Treatment | Developing therapies for Gaucher disease, Fabry disease, and other lysosomal storage disorders |
| Innovative Technology | Utilizing ProCellEx plant-based protein expression system |
| Patient-Centric Approach | Addressing unmet medical needs in rare genetic disorders |
Technology Platform Capabilities
- ProCellEx platform capable of producing complex recombinant proteins
- Cost-effective protein manufacturing process
- Ability to generate glycoprotein therapeutics
Key Product Development Statistics
Financial data for Protalix BioTherapeutics, Inc. (as of 2024):
| Metric | Value |
|---|---|
| Market Capitalization | $72.3 million |
| Research & Development Expenses | $24.1 million |
| Number of Active Clinical Trials | 3 ongoing rare disease programs |
Strategic Focus Areas
- Taliglucerase alfa (FDA-approved Gaucher disease treatment)
- PRX-102 for Fabry disease
- OPRX-106 for inflammatory bowel diseases
Key Technological Advantage: ProCellEx platform enables production of complex recombinant proteins using plant cell culture technology.
Vision Statement of Protalix BioTherapeutics, Inc. (PLX)
Vision Statement Components of Protalix BioTherapeutics, Inc. (PLX)
Innovative Rare Disease Therapeutics DevelopmentProtalix BioTherapeutics focuses on developing proprietary therapeutic proteins for rare and specialized genetic disorders.
| Key Focus Areas | Current Status |
|---|---|
| Rare Genetic Diseases | Primary Research Target |
| Proprietary Platform Technology | ProCellEx® Protein Expression System |
Research and Development Priorities
Targeted Therapeutic Platforms- Gaucher Disease Treatment
- Fabry Disease Intervention
- Genetic Disorders Management
Scientific Innovation Metrics
| R&D Investment | Amount |
|---|---|
| Annual R&D Expenditure | $24.3 million (2023) |
| Research Personnel | 42 specialized scientists |
Strategic Pipeline Development
Protalix maintains a focused approach on developing breakthrough therapies using plant-cell based manufacturing platforms.
| Clinical Stage Programs | Current Phase |
|---|---|
| PRX-102 (Fabry Disease) | Phase 3 Clinical Trials |
| ELELYSO® (Gaucher Disease) | FDA Approved Treatment |
Core Values of Protalix BioTherapeutics, Inc. (PLX)
Core Values of Protalix BioTherapeutics, Inc. (PLX) in 2024
Innovation and Scientific Excellence
Protalix BioTherapeutics demonstrates commitment to innovation through its proprietary ProCellEx protein expression platform.
| R&D Metric | 2024 Value |
|---|---|
| R&D Expenses | $14.3 million |
| Patent Applications | 7 active patents |
Patient-Centric Approach
Focused on developing rare disease therapies with targeted treatment strategies.
- Ongoing clinical trials for Gaucher disease treatment
- Personalized therapeutic development approach
- Patient support programs implementation
Ethical Pharmaceutical Development
Commitment to rigorous safety and compliance standards in drug development.
| Compliance Metric | 2024 Status |
|---|---|
| FDA Interactions | 12 formal regulatory communications |
| Clinical Trial Compliance Rate | 100% regulatory adherence |
Sustainability and Corporate Responsibility
Environmental and social responsibility integrated into corporate strategy.
- Reduced carbon footprint in manufacturing
- Ethical supply chain management
- Community health initiatives
Protalix BioTherapeutics, Inc. (PLX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.